Retrospective review of doxorubicin plus sorafenib as second-line therapy in hepatocellular carcinoma (HCC).
Ghassan K. Abou-Alfa
Consultant or Advisory Role - Bayer
Research Funding - Bayer
Jennifer Ma
No relevant relationships to disclose
Eileen Mary O'Reilly
Consultant or Advisory Role - Bayer (I)
Research Funding - Bayer (I)
Bolorsukh Gansukh
No relevant relationships to disclose
Joanne F. Chou
No relevant relationships to disclose
Marinela Capanu
No relevant relationships to disclose
Leonard Saltz
Research Funding - Bayer